Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Hepatoblastoma: early-phase trial registry

5 of 10 indexed Hepatoblastoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Hepatoblastoma: 10 US clinical trials tracked, 5 recruiting.

Hepatoblastoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Seattle Children's Hospital, running 3 of these trials.

Enrollment posture brief

Registry condition hepatoblastoma

OPEN 5 | RECR 50% | LATE 1 | EARLY 8 | RANK #1724 | SPON 3

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%Hepatoblastoma (this)50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Hepatoblastoma

Hepatoblastoma lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hepatoblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hepatoblastoma is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hepatoblastoma research.

    Seattle Children's Hospital accounts for 3 of 10 trials (30%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Hepatoblastoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 68 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.

  4. Hepatoblastoma research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 21Phase 31

Open and recent trials

10 total, page 1 of 1

RECRUITING 1,600 participants

Molecular Basis of Pediatric Liver Cancer

University of Pittsburgh

NCT03959800

RECRUITING Phase 1 21 participants

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Baylor College of Medicine

NCT06198296

RECRUITING Phase 1 21 participants

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Seattle Children's Hospital

NCT07148050

RECRUITING Phase 1 20 participants

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Valent Technologies

NCT04337177

RECRUITING Phase 1 15 participants

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

Eureka Therapeutics

NCT04634357

ACTIVE NOT RECRUITING Phase 3 537 participants

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Children's Oncology Group

NCT03533582

ACTIVE NOT RECRUITING Phase 2 109 participants

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

NCT02867592

ACTIVE NOT RECRUITING Phase 1 83 participants

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

NCT06521567

ACTIVE NOT RECRUITING Phase 1 68 participants

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Seattle Children's Hospital

NCT04483778

ACTIVE NOT RECRUITING Phase 1 44 participants

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Seattle Children's Hospital

NCT03618381

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Hepatoblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cobolimab Drug
1 trials
second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG Biological
1 trials
second generation 4-1BBζ EGFR806-EGFRt Biological
1 trials
Pharmacological Study Other
1 trials
second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG Biological
1 trials
second generation 4-1BBζ B7H3-EGFRt-DHFR Biological
1 trials
VAL-413 Drug
1 trials
ET140203 T Cells Drug
1 trials

US sites by state

Facility locations filed on Hepatoblastoma trials. A trial with sites in several states counts in each.

California 5 trials
Washington 3 trials
Ohio 2 trials
Arkansas 2 trials
Alabama 2 trials
Alaska 2 trials
Wisconsin 1 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hepatoblastoma page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatoblastoma condition card totals 10 registered trials; most-linked intervention Cobolimab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.